›› KLIFOVET › EXPERTISE › PUBLICATIONS

Multicenter Randomized, and Blinded European Field Study Evaluating the Efficacy and Safety of Felpreva®, a Novel Spot-On Formulation Containing Tigolaner, Emodepside, and Praziquantel in Treating Cats with Mixed Infection with Nematodes, Cestodes And/Or Lungworms

This paper describes a multicentric field study which has evaluated the safety and efficacy of a novel spot on formulation containing emodepside 2.04 w/v, praziquantel 8.14 w/v and tigolaner 9.79 w/v (Felpreva®, Vetoquinol) when administered at the intended commercial dose of 0.15 mL/kg body weight to privately owned cats infected by major intestinal nematodes (Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme, Uncinaria stenocephala) and/or tapeworms (Dipylidium caninum, Taenia taeniaeformis) and/or lungworms (Aelurostrongylus abstrusus, Troglostrongylus brevior). A total of 219 cats from 26 veterinary clinics located in Albania, Greece, Italy, Hungary and Portugal were included in the study. Faeces from the cats were examined on a single occasion between Study Day -7 and Study Day 0 (baseline) and post-treatment i) twice between day 7 and 14±2 (for intestinal helminths) or ii) twice between SD 21±2 and SD 28±2 (for lungworms). Cats were allocated in two groups in a ratio of 2:1 (Felpreva®: Profender®). Cats infected by intestinal helminths were treated once on SD0 i) with Felpreva® (Group 1) or ii) with a commercial control product Profender® (Group 2). Animals infected by lungworms received a second treatment with Profender® at SD 14 ±2 regardless the group allocation. Faecal egg or larval count reduction for Felpreva® was 97.47% for intestinal nematodes and 96.80% for lungworms. No cats infected by tapeworms at baseline resulted. positive after treatment with Felpreva®. However, the low number of cats (n=10) did not allow for a 52 statistical analysis to be performed. Non-inferiority of Felpreva® compared to Profender® was statistically demonstrated for all target intestinal and respiratory parasites. No adverse events nor application site reactions were observed. These results show that the new topical combination product Felpreva® is highly safe and efficacious in treating infections caused by major species of feline intestinal nematodes, cestodes and lungworms under field conditions. Electronic copy available at: https://ssrn.com/abstract=4064463

DATE » 19.01.2022

AUTHORS » Dejan Cvejića , Norbert Menckeb*, Gabriele Petryc , Hannah Ringeisenc , Hannah Hamburgc , Klaus Hellmanna , Donato Traversad , Simone Morellid , Angela Di Cesared , Anastasia Diakoue , Róbert Farkasf a Klifovet GmbH, Geyerspergerstr. 27, 80689 München, Germany b Vetoquinol, Department of Medical Marketing Parasitology, 37 rue de la Victoire, 75009 Paris, France c Bayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 15 Monheim, Germany d Faculty of Veterinary Medicine, University of Teramo, Località Piano d’Accio, 64100 Teramo (TE), Italy e Faculty of Health Sciences, School of Veterinary Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. f Faculty of Veterinary Medicine, Szent István University, Department of Parasitology and Zoology, István u. 2, Budapest 1078, Hungary

PUBLISHED » https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4064463